The point of care (POC) polymerase chain reaction (PCR) systems market in China is expected to grow at a compound annual growth rate (CAGR) of 10.6% between 2020 and 2025, driven by the effectiveness of POC analyzers in the rapid detection of infectious diseases specifically COVID-19, forecasts GlobalData, a leading data and analytics company.

GlobalData’s latest report, ‘POC Analyzers (In Vitro Diagnostics) – Global Market Analysis and Forecast Model (COVID-19 Market Impact)’, reveals that the POC PCR systems accounted for more than 20% of the Chinese POC analyzers market in 2020.

Roche Diagnostics International Ltd was the leading player in the Chinese POC PCR systems market in 2020, followed by Cepheid. Together these two companies accounted for around 95% of the market in 2020.

Anusha Kaushik, Medical Devices Analyst at GlobalData, comments: “Growth in the number of COVID-19 cases has increased the demand for faster and effective diagnostic techniques. Since the start of the pandemic, PCR systems have been the standard for rapid detection of infection and have been installed at a faster rate in hospitals, primary health centers and laboratories. The POC PCR systems are most effective in detecting COVID-19 due to their high sensitivity and specificity.”

POC PCR systems are also used for the diagnosis of human immunodeficiency virus, cancers, and hereditary diseases. In addition to suspected infectious cases, PCR systems are also used to screen pregnant women and donors of human cells, tissues, and source plasma donations. The growing application of POC PCR systems across multiple disease areas is expected to lead to higher usage of these devices.

Ms. Kaushik concludes: “POC testing is now widely used in emergency and critical care settings in China due to less turnaround time. This helps in improving therapeutic decision-making. The POC PCR systems market in China is expected to grow strongly during the forecast period, primarily due to the preparedness of healthcare facilities to fight against pandemics such as COVID-19, rising incidence of infectious diseases and strong ongoing demand for molecular diagnosis.”